Mean levels of CD4+T cells increased from 910.7 at baseline to 1000.2 cells/μL after the second dose of the COVID-19 vaccine in the ABB C1® group, whereas there was a decrease from 1055.1 to 929.8 cells/μL in the placebo group. This evidence concerns the gene CD4 and COVID-19.